Biomedical Engineering Reference
In-Depth Information
33. Gavrilyuk JI, Wuellner U, Salahuddin S, Goswami RK, Sinha
SC, Barbas CF, 3rd. (2009) An efficient chemical approach to
bispecific antibodies and antibodies of high valency. Bioorg.
Med. Chem. Lett. 19, 3716-3720.
34. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A,
et al. (2007) Simultaneous targeting of multiple disease medi-
ators by a dual-variable-domain Immunoglobulin. Nat.
Biotech. 25, 1290-1297.
35. Ghayur T. (2010) Drug Discovery and Development Week,
Burlingame, CA, 2010 August 3.
36. Ludwig D. (2010) Drug Discovery and Development Week,
Burlingame, CA, 2010 Aug 3.
37. Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P,
Bohlen P, et al. (2003) Di-diabody: a tetravalent bispecific
antibody molecule by design. J. Immunol. Methods 279,
219-232.
38. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR,
Bontadelli K, et al. (2010) Engineering of stable bispecific
antibodies targeting IL-17A and IL-23. Protein Eng. Des. Sel.
23, 115-127.
39. Michaelson JS, Dermarest SJ, Miller B, Amatucci A, Snyder
WB, Wu X, et al. (2009) Anti-tumor activity af stability-
engineered IgG-like bispecific antibodies targeting TRAIL-
R2 and LT-betaR. MAbs 1, 128-141.
40. Scheuer W. (2010) The NCI-EORTC-AACR Meeting in
Berlin, Germany, 2010 Nov 19.
41. Dinasi N. (2010) Sixth Annual PEGSummit, Boston MA, 2010
May 20-21.
42. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E,
Niwa R, Uchida K, et al. (2006) Fucose removal
from complex-type oligosaccharide enhances the antibody-
dependent cellular cytotoxicity of single-gene-encoded bispe-
cific antibodies linked to the antibody constant domain.
J. Biochem. 140, 359-368.
43. Lu H, Shi M, Wang M, Xie Z, Hu M, Yu M, et al. (2008) In
vitro and in vivo antitumor effect of a trivalent bispecific
antibody targeting ErbB2 and CD16. Cancer Biol. Ther. 7,
1744-1750.
44. Blankenship JW, Strobel S, Tan P, Grosmaire L, Simon A,
Clark C, et al. (2009) Anti-CD79B x anti-DR SCORPION
molecule: A single chain, bispecific immunotherapeutic with
potent in vitro activity against B-cell lymphoma. Poster at
100th Annual Meeting of the American Association for Cancer
Research, Abstract No. 5465.
45. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D,
Ostrander C, et al. (2010) A dual-targeting PDGFRbe-
ta/VEGF-A molecule assembled from stable antibody frag-
ments demonstrates anti-angiogenic activity in vitro and in
vivo. MAbs 2, 20-34.
46. Johnson S. (2010) Drug Discovery and Development Week,
Burlingame, CA, 2010 Aug 2-4.
47. Guo J. (2010) Third Annual Antibody Engineering and Ther-
apeutics Asia, Shanghai, China, 2010 Nov 11.
48. Roopenian DC, Akilesh S. (2007) FcRn: the neonatal Fc
receptor comes of age. Nat. Rev. Immunol. 7, 715-725.
49. Nimmerjahn F, Ravetch JV. (2008) Fcgamma receptors as
regulators of immune responses. Nat. Rev. Immunol. 8, 34-47.
50. Sebastian M, Passlick B, Friccius-Quecke H, Jager M,
Lindhofer H, Kanniess F, et al. (2007) Treatment of non-small
cell lung cancer oatients with the trifunctional monoclonal
antibody catumaxomab (anti-EpCAM x anti-CD3): a Phase I
study. Cancer Immunol. Immunother. 56, 1637-1644.
51. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al.
(2006) Engineered antibody Fc variants with enhanced effector
function. Proc. Natl. Acad. Sci. USA 103, 4005-4010.
52. Beckman RA, Weiner LM, Davis HM. (2007) Antibody con-
structs in cancer therapy: protein engineering strategies to
improve exposure in solid tumors. Cancer 109, 170-179.
53. Sheer J. (2010) The Sixth Annual PEGSummit in Boston, MA,
2010 May 20-21.
54. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH.
(2009) Hexavalent bispecific antibodies represent a new class
of anticancer therapeutics: 1. Properties of anti-CD20/CD22
antibodies in lymphoma. Blood 113, 6161-6171.
55. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg
DM. (2010) Recombinant bispecific monoclonal antibodies
prepared by the dock-and-lock strategy for pretargeted radio-
immunotherapy. Semin. Nucl. Med. 40, 190-203.
56. Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten S,
Mertens N. (2000) Fab chains as an efficient heterodimerization
domain scaffold for the production of recombinant bispecific and
trispecific antibody derivatives. J. Immunol. 165, 7050-7057.
57. Schanzer JM, Fichtner I, Baeuerle PA, Kufer P. (2006) Anti-
tumor activity of a dual cytokine/single-chain antibody fusion
protein for simultaneous delivery of GM-CSF and IL-2 to Ep-
CAM expressing tumor cells. J. Immunother. 29, 477-488.
58. Humphreys D. (2010) Antibody Engineering Conference, San
Diego, CA, 2010 Dec 8.
59. Nelson AL. (2010) Antibody fragments: hope and hype. MAbs
2, 77-83.
60. Mabry R, Snavely M. (2010) Therapeutic bispecific antibod-
ies: the selection of stable single-chain fragments to overcome
engineering obstacles. IDrugs 13, 543-549.
61. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren
F, Haber E, et al. (1991) Protein engineering of single-chain Fv
analogs and fusion proteins. Methods Enzymol. 203, 46-88.
62. Todorovska A, Roovers RC, Dolezal, O, Kortt, AA,
Hoogenboom, HR, Hudson, PJ. (2001) Design and application
of diabodies, triabodies and tetrabodies for cancer targeting.
J. Immunol. Methods 248, 47-66.
63. Baeuerle PA, Kufer P, Bargou R. (2009) BiTE: teaching anti-
bodies to engage T-cells for cancer therapy. Curr. Opin. Mol.
Ther. 11, 22-30.
64. Baeuerle PA, Reinhardt C. (2009) Bispecific T-cell engaging
antibodies for cancer therapy. Cancer Res. 69, 4941-4944.
65. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang
P, von Stackelberg A. (2010) Complete remission after blina-
tumomab-induced donor T-cell activation in three pediatric
patients with post-transplant relapsed acute lymphoblastic
leukemia. Leukemia, October 14 [Epub ahead of print].
Search WWH ::
Custom Search